<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220504054734N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-06-30</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>Low-level laser and extracorporeal shockwave in patients with carpal tunnel syndrome</public_title>
      <acronym></acronym>
      <scientific_title>The comparison of effectiveness of low-level laser and extracorporeal shockwave in patients with carpal tunnel syndrome</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-07-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>54</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/63381</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Those patients who will meet the study inclusion criteria will be  allocated randomly into 3 groups: the control group (routine conservative treatment group), low-level laser therapy group,  and  extracorporeal shockwave  group . A block balanced randomization (1:1:1) with a block size of 6 will be used for random allocation. A random allocation will be performed using the website of www.randomization.com. To conceal the sequence of the random allocation, numbered closed envelopes containing A, B, C groups will be used. Group A  will receive the routine conservative treatment,  group B will receive low-level laser therapy, and Group C  will receive extracorporeal shockwave, Blinding description: In the present study,  those who will assess the outcomes and will perform statistical analysis  are blinded while the therapist  and participants are not blinded.
To blind outcome assessor and the person who  will perform statistical analysis  : no information will be given about type of groups.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Carpal tunnel syndrome.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group:  This group will receive Low-level laser , five sessions  per week,  for two weeks.Each session will last for 5 minutes.  Patients will be asked to lay in sitting position  and the probe will be hold  between the distal crease and kaplan- cardinal line. Intervention 2: Intervention group:  This group will receive  extracorporeal shockwave  two sessions  per week,  for two weeks. Each session will last for 3-5 minutes.  Patients will be asked to lay in sitting position  and the probe will be hold on the flexor reticulum of the wrist. Intervention 3: Control group: The control group will receive routine treatments including mobilization, ultrasound (1MHz, 1 W/cm2, for 5 minutes) stretching techniques, hot pack, and TENS (25 minutes) five sessions  per week,  for two weeks.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is If the researchers of the secondary studies need to use the IPD, after the publication of the results of the study, the data file will be shared.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Ali Hossein Ghasemi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>School of Rehabilitation of Tehran University of Medical Science; Piche Shemiran; Enghelab street</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1148956111</zip>
        <telephone>+98 21 7752 8468</telephone>
        <email>ghasemi.amirhossien@yahoo.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Gholamreza Olyaei</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>School of rehabilitation of Tehran University of Medical Science; Piche Shemiran; Enghelab street</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1148956111</zip>
        <telephone>+98 21 7752 8468</telephone>
        <email>olyaeigh@tums.ac.ir</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients with carpal tunnel syndrome
Age between 20 and 60</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>History of fracture and dislocation in wrist and hand complex during the  last 3 months
History of surgery in wrist and hand complex during the  last 6 months
Cervical radiculopathy and thoracic outlet syndrome
Pregnancy
Receiving coricosteriod injection  and physiotherapy treatment during the last 3 months
Neurological and systemic diseases, such as rheumatoid arthritis, Parkinson, Multiple Sclerosis</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G56.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Carpal tunnel syndrome</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group:  This group will receive Low-level laser , five sessions  per week,  for two weeks.Each session will last for 5 minutes.  Patients will be asked to lay in sitting position  and the probe will be hold  between the distal crease and kaplan- cardinal line</i_keyword>
      <i_keyword>Intervention group:  This group will receive  extracorporeal shockwave  two sessions  per week,  for two weeks. Each session will last for 3-5 minutes.  Patients will be asked to lay in sitting position  and the probe will be hold on the flexor reticulum of the wrist.</i_keyword>
      <i_keyword>Control group: The control group will receive routine treatments including mobilization, ultrasound (1MHz, 1 W/cm2, for 5 minutes) stretching techniques, hot pack, and TENS (25 minutes) five sessions  per week,  for two weeks.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain. Timepoint: At baseline, after two weeks( the end of the treatment), after a one-week follow-up period. Method of measurement: Visual analog scale.</prim_outcome>
      <prim_outcome>Function. Timepoint: At baseline, after two weeks( the end of the treatment), after a one-week follow-up period. Method of measurement: Boston Carpal Tunnel Syndrome Questionnaire.</prim_outcome>
      <prim_outcome>Grip power. Timepoint: At baseline, after two weeks( the end of the treatment), after a one-week follow-up period. Method of measurement: Dynamometer.</prim_outcome>
      <prim_outcome>Pinch power. Timepoint: At baseline, after two weeks( the end of the treatment), after a one-week follow-up period. Method of measurement: Dynamometer.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Amplitude of median sensory nerve. Timepoint: At baseline, after two weeks (the end of the treatment). Method of measurement: Electromyography apparatus.</sec_outcome>
      <sec_outcome>Amplitude of median motor  nerve. Timepoint: At baseline, after two weeks (the end of the treatment). Method of measurement: Electromyography apparatus.</sec_outcome>
      <sec_outcome>Latency of median sensory  nerve. Timepoint: At baseline, after two weeks (the end of the treatment). Method of measurement: Electromyography apparatus.</sec_outcome>
      <sec_outcome>Latency of median  motor  nerve. Timepoint: At baseline, after two weeks (the end of the treatment). Method of measurement: Electromyography apparatus.</sec_outcome>
      <sec_outcome>Median nerve conduction velocity. Timepoint: At baseline, after two weeks (the end of the treatment). Method of measurement: Electromyography apparatus.</sec_outcome>
      <sec_outcome>Cross sectional area of median nerve. Timepoint: At baseline, after two weeks (the end of the treatment). Method of measurement: Sonography  apparatus.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-10-06</approval_date>
        <contact_name>Biomedical Research Ethics Committee of School of Nursing and Midwifery &amp; Rehabilitation of Tehran U</contact_name>
        <contact_address>Department of research and technology of Tehran University of Medical Sciences; Keshavarz Blvd; Ghods St Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
